IS SABR COST-EFFECTIVE IN OLIGOMETASTATIC CANCER? AN ECONOMIC ANALYSIS OF SABR-COMET

Qu, M; Chen, YJ; Zaric, G; Senan, S; Olson, R; Harrow, S; John-Baptiste, A; Gaede, S; Mulroy, L; Schellenberg, D; Senthi, S; Swaminath, A; Kopek, N; Liu, M; Warner, A; Rodrigues, G; Palma, D; Louie, A

RADIOTHERAPY AND ONCOLOGY, 2019; 139 (): S41